Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Schizophrenia

Trial begins to investigate efficacy of monoclonal antibody against schizophrenia

Natalizumab targets the microglial cells in the central nervous system which are overactive in people with multiple sclerosis and now found also to be overactive in people in the early stages of schizophrenia.

A two-year trial has begun to analyse the efficacy of a monoclonal antibody drug, currently used to treat multiple sclerosis, as a treatment for schizophrenia.

The trial, a collaboration between the Medical Research Council (MRC) and King’s College London, is based on emerging evidence that schizophrenia may be an immune disease. The drug, natalizumab, works by targeting microglia, a type of immune cell residing in the brain which are thought to be overactive in people at risk of developing schizophrenia and in the early stages of the disease. 

The first participant in the trial received his first dose of treatment at the beginning of November 2017, and 60 patients will be treated in total, attending clinic once a month for three months to receive hour-long infusions. Half of the participants will be given the drug and half will be given placebo and their symptoms will be tracked with brain scans, cognitive assessment and tests of immune activity.

“Fundamentally it is still unknown if activated microglia play a primary role in the symptoms and brain changes seen in schizophrenia or whether changes are a secondary phenomenon,” explains Oliver Howes, professor of molecular psychiatry at the MRC London Institute of Medical Sciences, consultant psychiatrist and senior researcher on the trial.

“The key test is to reverse microglial activation and determine the effect on symptoms and brain measures.

“To achieve this purpose we will use natalizumab, a monoclonal antibody that specifically targets microglia, coupled with in-vivo measures of microglial activity and clinical measures.”

It is hoped that the trial will explain whether microglial activation is linked to brain changes in schizophrenia, and if it is possible to reduce microglial activation in schizophrenia.

“It is clear we need to understand better other aspects of the pathophysiology of schizophrenia if we are to advance treatment,” said Howes.

Schizophrenia affects more than 50 million people in the world, yet was dubbed the ‘abandoned illness’ in a report by the UK’s Schizophrenia Commission in 2012 due to disinvestment in research and services.

“It is among the top causes of global disease burden in young adults, and a major cause of mortality: 5–10% die due to suicide,” said Howes.

“Contributing to the failure to reduce this high health and economic burden is the fact that current drug treatments, the antipsychotics, are inadequate for up to three-quarters of patients; either due to poor efficacy or poor tolerability.”

Howes explained that antipsychotics, many of which use the same mechanism of action first discovered over sixty years ago, only address one aspect of the illness and fail to improve negative symptoms such as cognitive impairment, or to prevent the excess of grey and white matter loss seen during the illness.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2017.20203911

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 1 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £138.50Buy now
  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 2 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £262.50Buy now
  • Health Economics

    Health Economics

    Health Economics is a practical analysis of the prominent economic issues facing the American health care system, and what mechanisms exist to counter it.

    £33.00Buy now
  • Conducting Your Pharmacy Practice Research Project

    Conducting Your Pharmacy Practice Research Project

    A systematic guide to the stages of the research process, from planning of the project through to dissemination of the findings.

    £26.00Buy now
  • Facilitating Learning in Healthcare

    Facilitating Learning in Healthcare

    Assist learning in healthcare effectively with this practical guide. Designed specifically for people from non-teaching backgrounds.

    £38.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • MS brain scan ss nov 17

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.